Skip to content
Home/Companies/Healthcare/Iambic Therapeutics
Iambic Therapeutics

Iambic Therapeutics

Healthcare·US·Active·3yr hold
Entry
2023
Hold
3yr
Status
Active

Who owns Iambic Therapeutics?

Iambic Therapeutics is currently owned by Abingworth through Abingworth Bioventures 8 (2021 vintage), since 2023.

Hand-verified · updated 2026-04-21

Abingworth
Investor
Abingworth
Abingworth Bioventures 8 · 2021 · Life Sciences VC

Key facts

HQIreland
SectorHealthcare
Websitewww.iambic.ai

More from Abingworth Bioventures 8

Other portfolio companies in the same fund.

Cytospire Therapeutics
Cytospire Therapeutics
Active
BiotechUK· 2026
AdvanCell
Active
BiotechAustralia· 2025
Antares Therapeutics
Active
BiotechUS· 2025
Solve Therapeutics
Active
BiotechUS· 2025
Timberlyne Therapeutics
Active
HealthcareUS· 2025
Myricx Bio
Myricx Bio
Exited 2026
BiotechUK· 2024
to

More PE-backed in AI/ML

Comparable ai/ml deals from other GPs.

1715 Labs
Exited 2023
Parkwalk AdvisorsUK
Ai Palette
Ai Palette
Active
AgFunder
AirWorks
AirWorks
Active
PSG EquityUS
Anthropic
Anthropic
Active
General AtlanticUS
ControlExpert
ControlExpert
Active
General AtlanticGermany
Conversica
Conversica
Active
PSG EquityUS
Track Iambic Therapeutics

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy Iambic Therapeutics?

7 strategic and 113financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on Iambic Therapeutics.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue